pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
s.r.o is a pharma organization headquartered in EU. Primary therapeutic focus areas include high blood pressure, increased blood clotting, Stable Ischemic Heart Disease. NovaPharmaNews links 5 clinical program(s), 0 drug
EU HQ
2020 Founded
18 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
Midazolam 1 mg, Psilocybine 5 mg
Phase 2 · small molecule · Stable Ischemic Heart Disease
Midazolam 1 mg, Psilocybine 5 mg for Stable Ischemic Heart Disease is a Phase 2 program (small_molecule) at s.r.o. with 1 ClinicalTrials.gov record(s).
Internal code RAFAEL
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- s.r.o.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stable Ischemic Heart Disease
- Status
- active
- Trials
- 1